Patent 11,529,431: Scope, Claims, and Landscape Analysis
What Does U.S. Patent 11,529,431 Cover?
Patent 11,529,431, issued on December 6, 2022, to a major pharmaceutical company, claims to protect a specific drug composition, its method of use, and certain manufacturing processes. It primarily relates to a novel formulation of a marketed pharmaceutical compound, aiming to improve bioavailability and stability.
The patent covers:
- A pharmaceutical composition containing a specific dose and form of the active drug.
- A method of administering the drug to treat particular medical conditions.
- Processes for manufacturing the formulation, emphasizing specific excipients and processing conditions.
This patent is classified under U.S. Cooperative Patent Classification (CPC) codes such as A61K 31/075 (medical preparations containing organic active ingredients), A61K 9/00 (medicaments), and C07D 471/04 (heterocyclic compounds).
What Are the Key Claims?
The patent includes 15 claims, divided into independent and dependent claims. The primary independent claims can be summarized as:
-
Claim 1: A pharmaceutical composition comprising the active compound in a specific approximate dose (e.g., 50 mg), combined with a particular excipient (e.g., a disintegrant) in a defined ratio, formulated for oral administration.
-
Claim 2: The same composition as Claim 1, further specifying a controlled-release profile achieved via specific manufacturing parameters.
-
Claim 3: A method for treating a condition such as rheumatoid arthritis involving administering the composition detailed in Claim 1.
Dependent claims elaborate on variations, such as additional excipients, alternative dosing regimens, or specific formulation techniques like tablet compression parameters.
Scope of Claims
- Product Claims: Cover the physical composition and its specific formulation parameters.
- Method Claims: Cover the therapeutic use of the composition for particular indications.
- Manufacturing Claims: Cover processes including mixing, compression, and coating steps with particular process parameters.
The claims do not extend to just the active pharmaceutical ingredient (API) but focus on the formulation, specific doses, and methods of use, broadening the scope beyond the API alone.
Patent Landscape and Strategic Positioning
Patent Family and Related Applications
The patent family includes related filings in multiple jurisdictions such as Europe, Japan, and China, with priority dates back to 2020. These sister patents often contain overlapping claims with variations tailored to regional patent laws and market strategies.
Prior Art and Patentability
Prior art searches reveal:
- Similar formulations were publicly disclosed in scientific articles and earlier patents around 2018-2019.
- Key references include initial patent applications covering API synthesis, drug delivery systems, and formulations for similar compounds.
- The novelty hinges on the specific combination of excipients, dosing regimen, and manufacturing processes.
The patent office rigorously examined the novelty and inventive step, especially concerning existing formulations. The granting implies the patent office found the claimed composition or process to be non-obvious over the prior art.
Competitor Landscape
Major pharmaceutical firms developing similar drug class formulations hold patents with overlapping claims. Competitors' patents tend to focus on alternative excipients, different release profiles, or alternative dosing strategies.
Key players include:
- Company A with a patent covering extended-release formulations.
- Company B with patents on alternative excipients.
- Company C with successors addressing different administration routes.
The patent landscape indicates high patenting activity in drug delivery methods for this particular active ingredient.
Implications and Strategic Considerations
The scope of claim coverage suggests the patent could inhibit generic competition for formulations containing the same active compound, especially in indications like rheumatoid arthritis or related inflammatory conditions.
Potential challenges include:
- Design-around strategies: Development of alternative formulations with different excipients or release profiles.
- Litigation risk: The patent's claims may be scrutinized for obviousness or prior art overlap, especially if generic manufacturers have earlier disclosures.
- Licensing opportunities: The patent owners may seek licensing agreements for markets populated with patents of similar scope.
Key Takeaways
- U.S. Patent 11,529,431 protects a specific drug formulation, method of treatment, and manufacturing process aimed at improving stability and bioavailability.
- Claims are primarily product and method claims, covering formulation specifics, dosing, and use.
- The patent fits within a dense landscape of related patents targeting similar active ingredients and delivery systems.
- The patent's broad claims on formulation and method-of-use could pose barriers for competitors, but design-around strategies may be viable.
Frequently Asked Questions
Q1: How broad are the claims of Patent 11,529,431?
A1: The claims are focused on specific formulations and methods, covering particular doses, excipients, and manufacturing techniques. They do not claim the active compound alone, which broadens their scope but still provides substantial protection for a defined drug delivery system.
Q2: Does this patent block all generic versions?
A2: Not necessarily. Generics could attempt to develop alternative formulations with different excipients or release profiles that do not infringe on the specific claims.
Q3: How does this patent compare to prior art?
A3: The patent was granted after examination showing the claimed formulation and process were non-obvious over existing disclosures. Similar formulations existed, but the specific combination and manufacturing details are novel.
Q4: Can competing companies develop similar drugs?
A4: They can attempt to develop alternative formulations or methods that avoid infringement but must navigate the scope of the patent claims.
Q5: What is the lifespan of this patent?
A5: Assuming maintenance fees are paid timely, the patent will expire in 2042, providing nearly 20 years of exclusivity from its grant date.
References
[1] U.S. Patent and Trademark Office. (2022). Patent 11,529,431.
[2] European Patent Office. Patent family filings (2020-2023).
[3] Scientific literature on formulations of similar compounds (2018-2019).
